{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:39:50Z","timestamp":1792571990153,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05727-3","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:48:40Z","timestamp":1790588920000},"page":"5647-5666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, green synthesis, and anticancer evaluation of novel sulfaguanidine-based heterocycles as multi-target inhibitors of the VEGFR-2\/PI3K\/AKT\/mTOR pathway"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-5512","authenticated-orcid":false,"given":"Walaa K.","family":"Elabd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurls E.","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sharaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Abdel-Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"5727_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/14756366.2021.2015342","volume":"37","author":"M Hagras","year":"2022","unstructured":"Hagras M, Saleh MA, Ezz Eldin RR et al (2022) 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J Enzyme Inhib Med Chem 37:380\u2013396. https:\/\/doi.org\/10.1080\/14756366.2021.2015342","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5727_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2024.43198","volume":"7","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, Ahmed KY, Kibret GD et al (2024) Global disparities of cancer and its projected burden in 2050. JAMA Netw Open 7:1\u201314. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43198","journal-title":"JAMA Netw Open"},{"key":"5727_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"M Nikolaou","year":"2018","unstructured":"Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E (2018) The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 35:309\u2013318. https:\/\/doi.org\/10.1007\/s10585-018-9903-0","journal-title":"Clin Exp Metastasis"},{"key":"5727_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104218","volume":"104","author":"MA El-Zahabi","year":"2020","unstructured":"El-Zahabi MA, Sakr H, El-Adl K et al (2020) Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 104:104218. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104218","journal-title":"Bioorg Chem"},{"key":"5727_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cytogfr.2024.07.005","volume":"78","author":"FH Shah","year":"2024","unstructured":"Shah FH, Lee HW (2024) Endothelial and macrophage interactions in the angiogenic niche. Cytokine Growth Factor Rev 78:64\u201376. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.07.005","journal-title":"Cytokine Growth Factor Rev"},{"key":"5727_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10121673","volume":"10","author":"F Shaik","year":"2020","unstructured":"Shaik F, Cuthbert GA, Homer-Vanniasinkam S et al (2020) Structural basis for vascular endothelial growth factor receptor activation and implications for disease therapy. Biomolecules 10:1\u201325. https:\/\/doi.org\/10.3390\/biom10121673","journal-title":"Biomolecules"},{"key":"5727_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106425","volume":"133","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao H, Hou S et al (2023) Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. Bioorg Chem 133:106425. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106425","journal-title":"Bioorg Chem"},{"key":"5727_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040481","author":"HO Tawfik","year":"2022","unstructured":"Tawfik HO, El-Hamaky AA, El-Bastawissy EA et al (2022) New genetic bomb trigger: design, synthesis, molecular dynamics simulation, and biological evaluation of novel bibr1532-related analogs targeting telomerase against non-small cell lung cancer. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph15040481","journal-title":"Pharmaceuticals"},{"key":"5727_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/1120009X.2023.2278014","volume":"36","author":"H Dou","year":"2024","unstructured":"Dou H, Yu P, Liu Y et al (2024) Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review. J Chemother 36:370\u2013388. https:\/\/doi.org\/10.1080\/1120009X.2023.2278014","journal-title":"J Chemother"},{"key":"5727_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00201","author":"MdelM Maldonado","year":"2020","unstructured":"Maldonado MdelM, Medina JI, Velazquez L, Dharmawardhane S (2020) Targeting Rac and Cdc42 GEFs in metastatic cancer. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2020.00201","journal-title":"Front Cell Dev Biol"},{"key":"5727_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2016.1187605","author":"R Ulus","year":"2016","unstructured":"Ulus R, Kaya M, Demir D et al (2016) Three-component synthesis and carbonic anhydrase inhibitory properties of novel octahydroacridines incorporating sulfaguanidine scaffold. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2016.1187605","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5727_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106397","volume":"133","author":"EM Husseiny","year":"2023","unstructured":"Husseiny EM, Abulkhair HS, El-dydamony NM, Anwer KE (2023) Bioorganic chemistry exploring the cytotoxic effect and CDK-9 inhibition potential of novel. Bioorg Chem 133:106397. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106397","journal-title":"Bioorg Chem"},{"issue":"10","key":"5727_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/ph17101284","volume":"17","author":"LH Al-wahaibi","year":"2024","unstructured":"Al-wahaibi LH, Elbastawesy MAI, Abodya NE et al (2024) New pyrazole\/pyrimidine-based scaffolds as inhibitors of heat shock protein 90 endowed with apoptotic anti-breast cancer activity. Pharmaceuticals 17(10):1284","journal-title":"Pharmaceuticals"},{"key":"5727_CR14","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra08997b","author":"M Elmowafy","year":"2026","unstructured":"Elmowafy M, El-adl K, Ahmed NM (2026) Pyrazole\/pyrimidine derivatives endowed with azobenzenes as dual EGFR T790M and VEGFR-2 inhibitors: anticancer, docking, synthesis, design and ADMET assessments. RSC Adv. https:\/\/doi.org\/10.1039\/d5ra08997b","journal-title":"RSC Adv"},{"key":"5727_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.70245","author":"KE Anwer","year":"2026","unstructured":"Anwer KE (2026) Ecofriendly synthesis of new azo compounds as antibacterial agents\u202f: in vitro screening and preliminary in vivo evaluation using 131I\u2010 radiolabeling. Arch Pharm. https:\/\/doi.org\/10.1002\/ardp.70245","journal-title":"Arch Pharm"},{"key":"5727_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.132513","volume":"1256","author":"KE Anwer","year":"2022","unstructured":"Anwer KE, Sayed GH, Ramadan RM (2022) Synthesis, spectroscopic, DFT calculations, biological activities and molecular docking studies of new isoxazolone, pyrazolone, triazine, triazole and amide derivatives. J Mol Struct 1256:132513. https:\/\/doi.org\/10.1016\/j.molstruc.2022.132513","journal-title":"J Mol Struct"},{"issue":"50","key":"5727_CR17","doi-asserted-by":"publisher","first-page":"35321","DOI":"10.1039\/d3ra06614b","volume":"13","author":"KE Anwer","year":"2023","unstructured":"Anwer KE, El-hddad SSA, El-sattar NEAA et al (2023) Five and six membered heterocyclic rings endowed with azobenzene as dual EGFRT790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations. RSC Adv 13(50):35321\u201335338. https:\/\/doi.org\/10.1039\/d3ra06614b","journal-title":"RSC Adv"},{"key":"5727_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108746","volume":"163","author":"E Tm","year":"2025","unstructured":"Tm E, Alsulaimany M, Athary F et al (2025) Bioorganic Chemistry ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo [1, 5- a ] pyrimidines substituted with furan and phenyldiazene as dual. Bioorg Chem 163:108746. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108746","journal-title":"Bioorg Chem"},{"key":"5727_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2026.2656826","author":"KE Anwer","year":"2026","unstructured":"Anwer KE, Ramadan RM, Nossier ES et al (2026) Design, synthesis, anticancer activity, tetrahydrobenzo [b ] thiophene carboxamides as CDK-2 inhibitors\u202f: in vitro and in silico DFT and molecular docking study. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2026.2656826","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5727_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2026.112608","volume":"233","author":"KE Anwer","year":"2026","unstructured":"Anwer KE, Abdelaziz G, Essa BM et al (2026) Design, eco-friendly synthesis, antibacterial evaluation, radiolabeling and biodistribution study of some novel enaminonitrile pyridine derivatives. Appl Radiat Isot 233:112608. https:\/\/doi.org\/10.1016\/j.apradiso.2026.112608","journal-title":"Appl Radiat Isot"},{"key":"5727_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-023-01053-7","author":"KE Anwer","year":"2023","unstructured":"Anwer KE, Sayed GH, Essa BM, Selim AA (2023) Green synthesis of highly functionalized heterocyclic bearing pyrazole moiety for cancer - targeted chemo \/ radioisotope therapy. BMC Chem. https:\/\/doi.org\/10.1186\/s13065-023-01053-7","journal-title":"BMC Chem"},{"key":"5727_CR22","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1080\/17568919.2024.2419363","volume":"16","author":"EM Husseiny","year":"2024","unstructured":"Husseiny EM, Abulkhair HS, El-sebaey SA et al (2024) In vivo evaluation of novel synthetic pyrazolones as CDK9 inhibitors with enhanced pharmacokinetic properties. Future Med Chem 16:2487\u20132505. https:\/\/doi.org\/10.1080\/17568919.2024.2419363","journal-title":"Future Med Chem"},{"key":"5727_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53228-4","author":"MM Mehany","year":"2024","unstructured":"Mehany MM, Hammam OA, Selim AA et al (2024) Novel pyridine bearing pentose moiety - based anticancer agents\u202f: design , synthesis , radioiodination and bioassessments. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-53228-4","journal-title":"Sci Rep"},{"key":"5727_CR24","doi-asserted-by":"publisher","first-page":"35321","DOI":"10.1039\/D3RA06614B","volume":"13","author":"KE Anwer","year":"2023","unstructured":"Anwer KE, El-hddad SSA, El-sattar NEAA et al (2023) RSC Advances Five and six membered heterocyclic rings endowed inhibitors\u202f: design, synthesis, in silico ADMET pro fi le. RSC Adv 13:35321\u201335338. https:\/\/doi.org\/10.1039\/D3RA06614B","journal-title":"RSC Adv"},{"key":"5727_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.mvr.2007.05.006","volume":"74","author":"AM Goodwin","year":"2007","unstructured":"Goodwin AM (2007) In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74:172\u2013183","journal-title":"Microvasc Res"},{"key":"5727_CR26","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.3892\/mmr.2022.12633","DOI":"10.3892\/mmr.2022.12633"},{"key":"5727_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.12622834278794","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.12622834278794","journal-title":"Methods"},{"key":"5727_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank nucleic acids research. Nucleic Acids Res 28:235\u2013242","journal-title":"Nucleic Acids Res"},{"key":"5727_CR29","unstructured":"The PyMOL Molecular Graphics System, Version 1.2r3pre, Schr\u00f6dinger, LLC."},{"issue":"1","key":"5727_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O'Boyle","year":"2011","unstructured":"O\u2019Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. J Cheminform 3(1):33","journal-title":"J Cheminform"},{"key":"5727_CR31","volume-title":"Discovery Studio Visualizer","author":"DS Biovia","year":"2019","unstructured":"Biovia DS (2019) Discovery Studio Visualizer. San Diego, USA"},{"key":"5727_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05727-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:46Z","timestamp":1792569346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05727-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5727"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05727-3","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All biological experiments involving human cell lines were conducted in accordance with the guidelines provided by the National Cancer Institute (NCI), Cairo, Egypt. No human subjects or live animals were involved in this study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}